VRTX News Alert Vertex Pharmaceuticals Inc (VRTX) 115.15 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vertex Pharmaceuticals Inc (VRTX) 115.15 $VRTX

Stock Market News for December 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:10AM CST
Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
KMI: 42.01 (+0.10), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), MON: 120.97 (-1.70), AMGN: 160.67 (+3.15), XOM: 93.78 (-0.81), BA: 131.24 (+1.21), SLB: 87.06 (-0.26), CELG: 109.60 (+3.48), LYB: 81.31 (-0.89), REG: 64.30 (-0.04), DD: 74.79 (-0.40), CVX: 113.47 (-0.48), OXY: 82.24 (-0.66), PX: 131.74 (-0.35), DOW: 46.01 (+0.03)

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)

After Yesterday's Decline of 2.51%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 3:55PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $109.34 to a high of $119.54. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $111.66 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 115.15 (+1.40)

Insider Buys And Sells: American Homes 4 Rent, Western Gas Partners
Asif Suria - at Seeking Alpha - Mon Dec 22, 3:50PM CST
Welcome to edition 235 of Insider Weekends. The prolific buying by insiders of energy companies lost some steam last week even as oil and energy stocks rebounded sharply along with the rest of the market. With the S&P 500 closing less than 5...
RH: 96.97 (-0.16), AMH: 17.34 (-0.07), VRTX: 115.15 (+1.40), CODI: 15.99 (-0.11), RES: 13.26 (-0.35), LJPC: 16.35 (-0.10), ICE: 221.73 (-1.70), WES: 73.08 (-0.25), ENH: 59.60 (-0.55), GHC: 877.19 (-0.76)

Vertex Pharmaceuticals Up 25.4% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Mon Dec 22, 9:45AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 25.44% as of today's recent price of $120.25.
VRTX: 115.15 (+1.40)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 4:36PM CST

NG: 2.82 (+0.10), VRTX: 115.15 (+1.40), NBR: 12.42 (-0.26), SAND: 3.19 (+0.32), MRKT: 26.55 (-0.14), NEM: 18.57 (+0.53), EDU: 20.35 (-0.04), DNR: 8.15 (-0.18), MCHX: 5.20 (-0.05), CRK: 7.01 (-0.20)

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 115.15 (+1.40), GALE: 1.49 (-0.02), EXAS: 27.60 (+0.39), ARIA: 6.81 (+0.15), MNKD: 5.68 (+0.18)

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 88.76 (+3.23), VRTX: 115.15 (+1.40), GILD: 91.29 (+1.84), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), SGMO: 14.20 (+0.14)

InsiderInsights.com Daily Round Up 12/16/14: XOMA, NS, TEP, RES
InsiderInsights - at Seeking Alpha - Wed Dec 17, 2:27PM CST

RH: 96.97 (-0.16), VRTX: 115.15 (+1.40), RES: 13.26 (-0.35), CCO: 10.19 (+0.34), HDS: 29.72 (+0.01), NS: 57.17 (+0.24), MFRM: 59.59 (+0.68), PCLN: 1,149.78 (+2.17), HERO: 1.05 (-0.02), TEP: 42.75 (+0.68), LC: 25.32 (+2.24), WIW: 11.28 (+0.03), FII: 33.86 (+0.26), HMTV: 12.81 (-0.03), DYN: 29.42 (+0.12), TWTR: 37.61 (+0.04), FOXF: 16.15 (+0.07), YUM: 72.79 (+0.11), WIA: 11.55 (+0.06), XOMA: 3.68 (+0.11)

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), NBIX: 21.33 (+0.09), GILD: 91.29 (+1.84), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), CTIC: 2.36 (+0.05), CEMP: 20.66 (+0.78), BMY: 59.15 (-0.01)

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 115.15 (+1.40), MYGN: 36.50 (+0.28), DNDN: 0.13 (-0.02), CTIC: 2.36 (+0.05), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Shares of VRTX Up 22.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 15, 9:18AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 22.41% as of today's recent price of $117.35.
VRTX: 115.15 (+1.40)

David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
Business Wire - Mon Dec 15, 8:01AM CST
Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, where he has served as Deputy Director and Chief Academic Officer since 2009. Dr. Altshuler is also currently a Professor of Genetics and Medicine at Harvard Medical School and an Adjunct Professor of Biology at the Massachusetts Institute of Technology and has been an attending physician at the Massachusetts General Hospital. His scientific research has been focused on the discovery of new pathophysiological processes underlying the risk of developing type 2 diabetes to identify and validate new drug targets. At Vertex, Dr. Altshuler will lead the company's research efforts aimed at discovering new medicines for the treatment of serious diseases, overseeing activities across the company's five research sites in the United States, Canada and Europe.
VRTX: 115.15 (+1.40)

Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user  Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)

Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.05% Yesterday
Comtex SmarTrend(R) - Thu Dec 11, 4:02PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.15 (+1.40)

After Yesterday's Rally of 3.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 11, 4:01PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.15 (+1.40)

Why Gilead Sciences and AbbVie Care About This Tiny Company
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 11, 9:18AM CST
Source: Gilead Sciences via Google Maps. Investors are focusing on AbbVie 's hepatitis C drug and its potential impact on Gilead Sciences ' hepatitis C market share if it wins FDA approval later this month. However, they might also want to keep...
VRTX: 115.15 (+1.40), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86)

Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), INCY: 71.57 (+1.99), AMGN: 160.67 (+3.15), ARRY: 4.64 (+0.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 573

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 100

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Secretariat's Legacy Bottled: Bourbon Honors Belmont Win

Updated Category News Views 28

A Toast to Racing History When you think about groundbreaking victories, Secretariat's name is right up there. Now, they’re bottling that history into bourbon. It's not just any day you get a drink inspired by a 31-length victory. Thoroughbred fans and whiskey lovers, listen up because Thirty-One Lengths Bourbon is bringing Secretariat back into the spotlight....

Continue Reading
China Automotive Systems Achieves Record Revenue in 2024

Updated Category News Views 202

Record Revenue Growth at China Automotive Systems China Automotive Systems, Inc. (NASDAQ: CAAS) has reported a remarkable increase in its revenue for the fiscal year 2024, achieving an all-time high of $650.9 million. This represents a significant 12.9% increase from the previous year's revenue of $576.4 million, demonstrating the company's strength in the competitive...

Continue Reading
Future of Energy Storage: A Market Growth Journey Ahead

Updated Category News Views 271

Understanding the Energy Storage Market Potential The global energy storage sector is on the brink of significant growth, projected to escalate from a value of USD 58.9 billion in 2024 to an astonishing USD 204.8 billion by 2033. This remarkable trajectory represents an impressive compound annual growth rate (CAGR) of 14.8%. As the world leans more heavily towards...

Continue Reading
Celebrated Legal Innovators: Reuben Raucher & Blum Shine Bright

Updated Category News Views 116

Reuben Raucher & Blum Earn Legal Visionary Recognition Boutique law firm Reuben Raucher & Blum (RRB), based in Los Angeles, has recently gained significant recognition for its exceptional legal expertise. Partners Tim Reuben and Stephanie Blum have been celebrated as Legal Visionaries in Business of Law magazine. This award acknowledges their remarkable leadership and...

Continue Reading
Baker Hughes Welcomes Ahmed Moghal as New CFO to Drive Growth

Updated Category News Views 294

Baker Hughes Announces New CFO Appointment HOUSTON and LONDON — Baker Hughes Company (NASDAQ: BKR) has officially appointed Ahmed Moghal as the new Chief Financial Officer. Moghal, who has been instrumental in the organization’s financial strategies as the CFO of Industrial & Energy Technology (IET), steps into this pivotal role immediately. His vast experience within...

Continue Reading